glp-1 agonists blindness risk The Effect of Semaglutide and RAs on of Nonarteritic Anterior Ischemic Optic Neuropathy GLP-1/GIP Receptor Agonists and Diabetic

Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study

Studies in patients with type 2 diabetes and obesity have demonstrated that the use of SGLT2 inhibitors, particularly empagliflozin, not only increases overall cancer risk but also significantly elevates the risk of bladder cancer [10, 108]

Data availability No datasets were generated or analyzed during the current study

And are we ready for a future where appetite itself is considered a chronic condition

Most drugs that enter Phase 1 do not reach approval

46,47 Thus, we fed ob/ob mice with the GAN diet to construct the NSAH model in the present study